NorthWest Biotherapeutics Inc (NWBO)

[dennisdave]

you are, again, falsely claiming that the rGBM endpoint as presented at the NY conference should be the same as the nGBM endpoint as approved and presented on the EMA/FDA website. I have already proved you wrong on that by copying both to see for you but you keep reporting this falsehood.


https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169688176


I guess you really are in need of reading glasses. No better reality check. From the NY Conference:

Secondary Endpoint: OS in recurrent GBM
Placebo arm crossovers* (n=64) vs. External controls (n=640)
*(Placebo arm patients received only SOC (control arms of external studies)
+ placebo until recurrence, then DCVax-L)

At the NY conference, the secondary endpoint for nGBM was not mentioned. Get a pair of reading glasses, +5 will do. If you are eager to learn with the second endpoints for nGBM is

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169688051

Monday, August 15, 2022
EU/UK and US endpoints do not differ

EU/UK/
The first secondary objective is to compare overall survival (OS) between patients randomized to placebo who received DCVax-L treatment following disease recurrence and control patients from comparable, contemporaneous clinical trials, in patients with recurrent GBM.

US
1. The first secondary objective is to compare overall survival (OS) between patients randomized to placebo who received DCVax-L treatment following disease recurrence, and control patients from comparable, contemporaneous clinical trials, in recurrent GBM.
[ Time Frame: Until death ]

exact the same
It has been stated more than once by the company and LL that the SAP is the same with every RA